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g.2013.0Abstract Occult hepatitis B virus infection (OBI) has been reported among patients with chronic
hepatitis C virus (HCV) infection and hepatocellular carcinoma (HCC). This study aimed to eval-
uate the prevalence of OBI in chronic hepatitis C patients with and without hepatocellular carci-
noma. A total of 40 chronic hepatitis C patients who were negative for HBsAg, were enrolled
into the study. They were classiﬁed into two groups: Group I which included 20 patients with
chronic hepatitis C only whereas Group II included 20 patients with chronic hepatitis C and
HCC. Detection of HBV DNA was done by nested-PCR using two sets of primers speciﬁc for sur-
face and X viral genomes in serum and liver tissue of patients. Genotyping system based on PCR
using type-speciﬁc primers was done for HBV-DNA positive intrahepatic samples. OBI was
detected in the liver tissue in 23/40 (57.5%) of chronic HCV infected patients, 18 (78.3%) of whom
belonged to group II, conferring a 90% prevalence of this group. In serum, HBV-DNA was
detected in 9/40 patients (22.5%), 7 (77.8%) of whom belonged to group II. Among the 23 positive
intrahepatic HBV-DNA samples studied, HBV-genotype D (34.8%) and B (26.1%) were more pre-
dominant, whereas HBV-genotype C (13.1%) and A (8.7%) infections were the least observed,
respectively; mixed genotypes were detected in 17.4% (n= 4), 3 of them were with HBV-genotype
D and B, and 1 was with HBV-genotype C and A.
In conclusion OBI is a fact in our community; it was detected in liver tissue of chronic HCV-
infected patients, especially in cases of chronic HCC. In addition, OBI might be related to severity
of necroinﬂammatory activity and ﬁbrosis. Large studies are needed to conﬁrm that co-infection
could determine a worse progress of chronic liver disease in this population. Also, detection of
intrahepatic HBV-DNA is more useful in diagnosis of OBI.
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Hepatitis B and C viruses (HBV and HCV) are the main etio-
logical agents of chronic hepatitis related to the emergence of
liver cirrhosis and hepatocellular carcinoma (HCC). Despite
careful investigations into the etiological factors for chronic li-in Shams University.
354 S.E. Taha et al.ver disease, in 5–10% of cases no etiological factor is detected.
However, this index may be smaller if molecular tests are per-
formed in search of occult infection with HBV in this popula-
tion [1].
Occult hepatitis B virus infection (OBI) is deﬁned as the
presence of hepatitis B virus (HBV) DNA in the liver of pa-
tients with negative results of hepatitis B surface antigen
(HBsAg) test with or without serological markers of previous
viral exposure [2]. In most cases, OBI is related to low level
HBV infection with sub-detectable levels of HBsAg and not
infection with HBV variants that cannot express S proteins
or produce S proteins with aberrant epitopes which are not de-
tected by conventional serological assays [3].
OBI may be involved in several clinical contexts; reactiva-
tion of the infection and consequent development of the
HBV-related liver disease; transmission of the ‘‘occult’’ virus
mainly through blood transfusion and orthotopic liver trans-
plantation with consequent hepatitis B in the recipient; the ef-
fect on occurrence and progression of the chronic liver disease;
and the role in hepatocarcinogenesis [4].
OBI has been found in individuals without HBV serological
markers, past HBV infection, and with HCC patients with or
without chronic hepatitis C (CHC) [5]. OBI has been found
with a high prevalence in patients with chronic hepatitis C
(CHC), probably because both HBV and hepatitis C virus
(HCV) share the same parenteral way of transmission. In par-
ticular, HBV DNA is detectable in about one-third of CHC
patients with negative results of HBsAg test in the Mediterra-
nean basin [6]. OBI in patients with chronic HCV infection
may be associated with more severe liver damage and even
the development of HCC [7].
Despite evidence that co-infection with HBV and HCV may
accelerate the progress to liver disease [8], be related to the
emergence of HCC [9], and adversely inﬂuence the response
to HCV treatment [6], there is still a debate on the conse-
quences of occult HBV infection in patients with chronic liver
disease by HCV. Studies are warranted to understand the sig-
niﬁcance of occult HBV infection better, and to clarify the pos-
sible role exerted by this cryptic infection on the outcome of
liver disease and hepatocellular carcinoma development [10].
It has been reported that in individuals with OBI, the DNA
level in peripheral blood is usually fewer than 103 copies/mL
and as low as 1000 copies per 1 lg of DNA extracted from li-
ver tissue. Advances in detection technologies in the past dec-
ade have allowed greater insight into OBI [11]. The frequency
of detection of HBV DNA is higher in liver tissue than in ser-
um [12].
The molecular basis of OBI is related to the long-lasting
persistence in the nuclei of hepatocytes of the viral cova-
lently-closed-circular DNA (cccDNA) [13]. Almost all OBI
cases are infected with replication-competent HBV showing
strong suppression of replication and gene expression, proba-
bly due to host immune-surveillance and epigenetic factors
[12].
On the basis of HBV antibody proﬁle, OBI may be distin-
guished in seropositive-and seronegative-OBI; the former is
positive for hepatitis B core and/or s antibodies, the latter is
negative for all markers of HBV infection besides very low
amount of HBV DNA (<200 IU/ml) [14]. Seronegative-OBI
cases may have either progressively lost HBV speciﬁc antibod-
ies after the resolution of an acute infection or, theoretically,
had negative results of tests from the beginning of infection,similar to what has been observed in the woodchuck model
of hepadnavirus infection with the woodchuck hepatitis virus
[15], where a low-dose infection was insufﬁcient to allow the
maturation of an antiviral protective memory response [16].
AlthoughOBI status is signiﬁcantly associated with the pres-
ence of antibodies toHBV [5], the analysis of liverDNA extracts
represents the gold standard for occult HBV evaluation [14].
Hence, serumanalysismust be taken into account only in the ab-
sence of liver specimens. In any case, it is strongly recommended
to use a highly sensitive nested polymerase chain reaction (PCR)
or real time PCRwith oligonucleotide primers speciﬁc for differ-
ent HBV genomic regions and complementary to highly con-
served nucleotide sequences [17].
The purpose of this study was to assess the prevalence of
OBI among chronic hepatitis C patients with and without
hepatocellular carcinoma.
2. Subjects and methods
2.1. Study design and population
This cross-sectional study was conducted on forty Egyptian
patients with chronic HCV infection in the period from Janu-
ary 2012 to February 2013. The study was held in the Internal
Medicine Clinic of Ain Shams University (Cairo, Egypt). It
was approved by the Hospital Ethics Committee of Ain Shams
University Hospitals (ASUHs) and an informed consent was
obtained from all subjects participating in this study. Inclusion
criteria were: an age of 18 years or over, proven HCV infection
based on viral load and HCV antibody (Ab), negative for hep-
atitis B surface antigen (HbsAg) and negative for HIV anti-
body. Exclusion criteria: history of alcohol abuse, the use of
potentially hepatotoxic drugs, patients with autoimmune hep-
atitis, hemochromatosis, alpha-1-antitrypsin deﬁciency or Wil-
son disease.
Diagnosis of chronic HCV infection was based on standard
serological assays and abnormal serum aminotransferase levels
in some patients (P1.5 times the upper limit of normal) for at
least 6 months [18]. All patients were positive for HCV anti-
bodies by the third generation enzyme linked immunosorbant
assay (Orth. HCV 3.0 Orth., Raritan, NJ, USA) with infection
conﬁrmed by polymerase chain reaction and was quantitated
in all patients using the amplicor HCV monitor assay (Roche,
Diagnostic Systems, Branchburg, NJ, USA) then categorized
as follows: weak viremia patients had 600–200,000 IU/ml,
those with moderate viremia had 200,000–2 million IU/ml
and those with high viremia had more than 2 million IU/ml.
The study population was classiﬁed into two main groups:
 Group I: 20 patients with chronic hepatitis C who were in
pre-treatment evaluation with no evidence of hepatic mass
lesions suspicious for HCC.
 Group II: 20 patients with chronic hepatitis C and HCC
evaluated on admission for surgical resection of tumor, or
liver nodule biopsy.
For all subjects in the study the following was done:
1. Detailed history taking and thorough clinical examina-
tion, symptoms and signs of chronic liver disease
(Jaundice, fatigue, encephalopathy).
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(CBC), liver function tests [serum aspartate amino-
transferase (AST), alanine aminotransferase (ALT),
alkaline phosphatase (ALP), albumin, and bilirubin]
and also a fetoprotein.
3. Abdominal ultrasound, abdomen computed tomogra-
phy or magnetic resonance imaging to detect hepatic
mass lesions suspicious for HCC.2.2. Specimens
 A peripheral venous blood sample was collected into a tube
containing EDTA.
 At the same time, ultrasound guided percutaneous liver
biopsy was performed as a part of pre-treatment evaluation
for HCV infection for histopathological analysis of the
lesions and for further analysis of HBV DNA by PCR.
Biopsy specimens were ﬁxed in buffered formalin and
embedded in parafﬁn.
The degree of inﬂammation and ﬁbrosis were assessed and
graded according to Franciscus [19]. Patients were divided
according to the necroinﬂammatory score of the liver biopsy
into three groups: patients with mild necroinﬂammatory activ-
ity (Score 1–8), patients with moderate necroinﬂammatory
activity (Score 9–12), and patients with severe necroinﬂamma-
tory activity (Score 13–18). They were also subdivided as re-
gards ﬁbrosis stage of the liver biopsy into: patients with
mild ﬁbrosis (Stage 0–1), patients with moderate ﬁbrosis (Stage
2–4) and patients with severe ﬁbrosis (Stage 5 or 6).
2.3. Detection of occult HBV DNA by nested PCR
In our study detection of HBV DNA was done by nested-PCR
using two sets of primers (Table 1) speciﬁc for surface and X
viral genomes regions, respectively, in both serum and tissue
specimens as previously described by Kazemi-Shirazi et al.
[20]. Usually, the genes ampliﬁed by PCR are S and X; the for-
mer has been found to be the most sensitive in serum, and the
second has been described as the most sensitive in the liver [6].
The preferred lower limit of detection (LLOD) for HBV is
5 IU/mL [21].
2.3.1. DNA extraction
DNA was extracted from the serum by QIAGEN viral DNA
extraction kit (Qiagen GmbH, Hilden, Germany) using
200 ll of the patient serum following the manufacturer’s
instructions. DNA was extracted from liver tissue by DNAaseTable 1 Sequences of primer pairs used for HBV PCR detection.
Gene Sequence
Surface gene S-1s: 50AGAACATCGCAT
S-2a: 50CATAGGTATCTT
S-3s: 50AGGACCCCTGCT
S-4a: 50AGATGATGGGAT
X gene X1s: 50CTAGCCGCTTGT
X2a: 50TTATGCCTACAG
X3s:50GGTCTTACATAAG
X4a: 50GTTCACGGTGGT
s: sense; a: antisense.Tissue kit (Qiagen, Hilden, Germany) according to the manu-
facturer’s instructions. In brief as regards DNA extraction
from liver tissue, 50 mg tissue specimens were homogenized
in buffer (150 mmol/L NaCl, 50 mmol/L Tris–HCl (pH7.4),
10 mmol/L EDTA, 1% SDS), and incubated overnight with
proteinase K (800 lg/mL) at 37 C. After extraction with phe-
nol/chloroform the nucleic acids were precipitated with etha-
nol. Nucleic acids were then resuspended and digested with
pancreatic ribonuclease (100 lg/mL) followed by extraction
with phenol/chloroform, and re-precipitation in pure cold eth-
anol. The DNA was resuspended in 10 mmol/L Tris–HCl (pH
7.4), 1 mmol/L EDTA, and its concentration was determined
by using a UV spectrophotometer (Nanodrop). Ampliﬁcation
of the b-actin gene was done to test the presence of artifacts
and to set a baseline for tissue sample that enables the evalua-
tion of the target genes in the HBV PCR. The ampliﬁed prod-
ucts were visualized on an ethidium bromide stained 2%
agarose gel.2.3.2. Determination of HBV genotypes
In this study we investigated the presence of HBV DNA geno-
types A–F. TheDNA extracted from liver tissues of patients po-
sitive for HBV DNA (n= 23) was subjected to nested PCR
according to the described method by Naito et al. [22]. The se-
quences of PCR primers used in this study are shown in Table 2.
In brief, the ﬁrst and second- round PCR primers were designed
on the basis of the conserved nature of nucleotide sequences in
regions of the pre-S1 through S genes, irrespective of the six
HBV genotypes. P1 and S1–2 were universal outer primers. B2
was used as the inner primer with a combination called mix A
for genotypes A–C. The ﬁrst PCR was carried out in 40 ul of a
reaction mixture containing 100 ng of each outer primer, a
200 mM concentration of each of the four deoxynucleotides,
2.5 UofTaqDNApolymerase (Promega, France) 1 · PCRbuf-
fer containing 50 mM KCl, 10 mM Tris pH 8.3) and 1.5 mM
MgCl2. The cycling protocol included one cycle of 5 min at
95 C, followed by 40 cycles consisting of 94 C for 1 min,
55 C for 1 min and 72 C for 2 min. Two second-round PCRs
were performed for each sample, with the common universal
sense primer (B2) andmixA for types A throughC and the com-
mon universal antisense primer (B2R) and mix B for types D
through F. A 1 ul aliquot of the ﬁrst PCR product was added
to two tubes containing the second sets of each of the inner pri-
mer pairs, each of the deoxynucleotides, Taq DNA polymerase,
and PCRbuffer, as in the ﬁrst reaction. These were ampliﬁed for
40 cycles with the following parameters: preheating at 95 C for
5 min, 30 cycles of ampliﬁcation at 94 C for 1 min, 58 C for
1 min, and 72 C for 1.30 min. Genotypes of HBV for each sam-Ampliﬁed segment
CAGGACTC30 159–178
GCGAAAGC30 642–623
CGTGTTAC30 181–200
GGGAATAC30 619–600
TTTGCTCG30 1282–1301
CCTCCTAG30 1666–1647
AGGACTC30 1518–1537
CTCCAT30 1625–1608
Table 2 HBV genotyping primer sequence.
Primer sequence (Position, speciﬁcity, and polarity)
First PCR
P1 50-TCA CCA TAT TCT TGG GAA CAA GA-30 (nt 2823–2845, universal, sense)
S1-2 50-CGA ACC ACT GAA CAA ATG GC-30 (nt 685–704, universal, antisense)
Second PCR
Mix A
B2 50-GGC TCM AGT TCM GGA ACA GT-30 (nt 67–86, types A–E speciﬁc, sense)
BA1R 50-CTC GCG GAG ATT GAC GAG ATG T-30 (nt 113–134, type A speciﬁc, antisense)
B1R 50-CAG GTT GGT GAG TGA CTG GAG A-30 (nt 324–345, type B speciﬁc, antisense)
BC1R 50-GGT CCT AGG AAT CCT GAT GTT G-30 (nt 165–186, type C speciﬁc, antisense)
Mix B
BD1 50-GCC AAC AAG GTA GGA GCT-30 (nt 2979–2996, type D speciﬁc, sense)
BE1 50-CAC CAG AAA TCC AGA TTG GGA CCA-30 (nt 2955–2978, type E speciﬁc, sense)
BF1 50-GYT ACG GTC CAG GGT TAC CA-30 (nt 3032–3051, type F speciﬁc, sense)
B2R 50-GGA GGC GGA TYT GCT GGC AA-30 (nt 3078–3097, types D–F speciﬁc, antisense)
Figure 1 Distribution of HBV genotypes in positive intrahepatic
HBV-DNA samples.
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bands. The two different second-round PCR products from
one sample were visualized on an ethidium bromide-stained
3% agarose gel.
2.4. Statistical analysis
Analysis of data was done by using a personal computer soft-
ware package (Statistical version 5, Stat Soft Inc. USA 1995).
The data obtained were expressed as descriptive statistics
(mean ± standard deviation). Statistics included two tailed un-
paired t-test for comparison between two groups. Chi-square
test (v2) was used for comparing and correlating categorical
parameters, respectively. A p value<0.05 was considered statis-
tically signiﬁcant and p> 0.05 was considered non signiﬁcant.
3. Results
From the forty patients enrolled in the present study, 24 were
males (60%) and 16 were females (40%) with mean age of
49.78 ± 5.04 years.
In serum, HBV DNA was detected in nine out of 40 pa-
tients (22.5%). As regards intrahepatic HBV DNA, it was de-
tected in 23 out of 40 (57.5%), 4/40 of them had surface (S)
gene (10%), 11/40 had X gene (27.5%), while 8/40 had both
X and S genes (20%). X gene was detected in four patients
within group I and in 15 patients within group II.
Furthermore, HBV DNA-positive was found more fre-
quently in patients within group II (HCC) as we analyzed
the prevalence of occult infection in this group and found that
7/9 of serum positive patients (77.8%) were in this group while
18/23 of intrahepatic positive samples (78.3%) were also in this
group.
Among the 23 positive intrahepatic HBV-DNA samples
studied, the distribution of HBV genotypes showed that,
OBI are predominantly caused by HBV-genotype D and B that
constituted (n= 8, 34.8%) and (n= 6, 26.1%), respectively.
Whereas HBV-genotype C and A were the least detected and
constituted (n= 3, 13.1%) and (n= 2, 8.7%) respectively,
while; mixed genotypes were detected in 17.4% (n= 4), three
cases with HBV-genotype D and HBV-genotype B and one
case with HBV-genotype C and HBV-genotype A. No other
genotypes were detected (Fig. 1).Among the various clinical characteristics, comparative
study between the HBV DNA-positive and DNA-negative pa-
tients revealed statistically highly signiﬁcant difference as re-
gards the age, prothrombin time and the platelet counts
(p< 0.001). While, total bilirubin, direct bilirubin, serum
albumin and serum HCV RNA levels showed signiﬁcant dif-
ference. However, there was non signiﬁcant difference regard-
ing gender, ALT, AST and ALP as shown in Table 3.
Comparison between patients with different grades of necr-
oinﬂammatory activity and stages of ﬁbrosis according to the
detection of intrahepatic HBV DNA was done as shown in Ta-
bles 4 and 5. We noticed a higher percentage of positive intra-
hepatic HBV-DNA samples among patients with severe
necroinﬂammatory activity (n= 15) than among patients with
moderate and mild necroinﬂammatory activity (n= 6 & 2
respectively) (Fig. 2). Also, a higher percentage of positive
intrahepatic HBV-DNA samples was observed in severe ﬁbro-
sis (n= 19) than in moderate and mild ﬁbrosis (n= 3 & 1
respectively) (Fig. 3).
4. Discussion
There is an increasing interest in OBI due to the increasing evi-
dence of its clinical relevance. This can be divided into four
Table 3 Characteristics of HCV-infected patients (with and without occult HBV infection).
Laboratory tests Positive Intrahepatic HBV DNA (n= 23) Negative Intrahepatic HBV DNA (n= 17) P value Signiﬁcance
Age (years) 51.74 ± 3.89 47.12 ± 5.29 0.0029 HS
Gender
Male (n= 24) 14 10 0.8961 NS
Female (n= 16) 9 7
ALT(IU/L) 82.22 ± 35 63 ± 32.13 0.0836 NS
AST(IU/L) 136.21 ± 84.11 102.02 ± 64.04 0.1694 NS
ALP (IU/L) 115.11 ± 31.74 97.35 ± 47.84 0.1661 NS
Total bilirubin (mg/dL) 1.79 ± 0.970 1.16 ± 0.34 0.0147 S
Direct bilirubin (mg/dL) 0.864 ± 0.314 0.541 ± 0.445 0.0104 S
Prothrombin time (%) 13.884 ± 1.65 12.21 ± 1.421 0.0018 HS
Albumin (g/dL) 3.646 ± 0.355 4.061 ± 0.743 0.0242 S
Platelets (/mm3) 112.333.33 ± 68.291.65 183.691.89 ± 82.505.63 0.0049 HS
Serum HCV RNA (copy/ml) 22.652.73 ± 10.376.61 14.603.33 ± 8.604.63 0.0131 S
Table 4 Comparison of degree of necroinﬂammatory activity regarding presence of OBI.
Necro-inﬂammatory activity index Occult HBV positive (n= 23) Occult HBV negative (n= 17)
Mild (Score 0–8) 2 (8.6%) 3 (17.6%)
Moderate (Score 9–12) 6 (26.2%) 6 (35.3%)
Severe (Score 13–18) 15 (65.2%) 8 (47.1%)
Table 5 Comparison of degree of ﬁbrosis regarding presence of OBI.
Fibrosis stages Occult HBV positive (n= 23) Occult HBV negative (n= 17)
Mild (Stage 0–1) 1 (4.3%) 5 (29.4%)
Moderate (Stage 2–4) 3 (13.1%) 4 (23.5%)
Severe (Stage 5 or 6) 19 (82.6%) 8 (47.1%)
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tion of occult HBV infection, its link to chronic liver diseases,
and its link to hepatocellular carcinoma [23].
As HBV and HCV share similar transmission routes, co-
infection with the two viruses is not a rare event in areas where
the two viruses are endemic and among subjects with high risks
of parenteral infections [24]. The importance of an association
between HBV and HCV lies in the fact that although HBV vir-
al load in occult infection is often low, a greater likelihood of
progression to cirrhosis and to HCC is observed when these
patients are compared with those infected only with HCV [1].
The prevalence of the intrahepatic HBV-DNA in the cur-
rent study among CHC patients was 57.5% while it was
22.5% in serum samples. Similarly, OBI prevalence in HCV
patients is reported to be 28.1–50% in liver tissue [11,25,26].
While, it was reported that 26.2–43.6% had detectable HBV
DNA in serum [27–29]. In the study of Fang et al. [30],
28.3% of cryptogenic chronic liver disease patients and
70.4% of HBsAg-negative HCC patients were positive for
HBV DNA in serum. Similarly, Bre´chot et al. [2] reviewed
some studies and concluded that about 20–30% of serum
and 40–50% of liver tissue showed HBV DNA positivity in
anti-HCV positive patients. Also, Hassan et al. [31] reported
that intrahepatic occult HBV-DNA was detected in 62.5%,
whereas; serum occult HBV-DNA was detected in only
22.5% of HCC patients.
However, other reports revealed prevalence of OBI rang-
ing from 6.7–14.8% among chronic HCV patients [32–34].While, Ferreira et al. [35] observed a lower rate (2.7%) in
non- injecting drug users in Brazil. In the study of Rossi
et al. [36], OBI was observed in 10% among patients with
chronic lymphocytic leukemia. Whereas in the study of Ro-
man et al. [37], OBI was detected in 14.2% of the native pop-
ulation sample in Mexico. Also, De Matos et al. [38] detected
serum occult HBV DNA in 12.7% of injecting drug users in
Brazil.
The patterns of local endemicity for HBV infection in the
populations of the different geographic areas, the patients’
sample investigated in each study, and the methodological dif-
ferences between studies may explain the observed discrepan-
cies in the rates of OBI among populations. Furthermore,
among certain patient groups, the prevalence of occult HBV
infection would likely be signiﬁcantly higher.
In this study, HBV DNA-positive was found more fre-
quently in patients within group II (HCC) as 7/9 (77.8%) of
serum positive patients and 18/23 (78.3%) of intrahepatic po-
sitive samples were in this group. X gene was detected in four
patients of group I and in 15 patients within group II.
Growing evidence suggests a high prevalence of occult B
infection in HCV-infected patients with HCC as there is ob-
served high proportion of HCV-related HCC cases show
OBI [39–42]. Similarly, the prevalence of OBI was evaluated
in CHC patients with and without HCC and found that
77.7% of them were with HCC [1]. Furthermore, other studies
from Japan and Italy showed the reported frequency of HBV
DNA detection in the liver of HBsAg-negative, anti-HCV-po-
Figure 2 Percentage of occult HBV infection in different grades
of necroinﬂammatory activity.
Figure 3 Percentage of occult HBV infection in different grades
of ﬁbrosis.
358 S.E. Taha et al.sitive patients ranged from 15% to 49% [43] for patients with-
out HCC and up to 73% among patients with HCC [44].
In the current study, no follow up was done for group I pa-
tients who were co-infected with chronic HCV and OBI to de-
tect its association with development of HCC. However, most
[21,28,40,45,46] but not all [9,34,47,48] studies from Asia and
Europe have found that patients with hepatitis C who had
detectable HBV DNA in the liver or serum had an increased
risk of HCC. One of the markers in HCC cases, is the presence
of the HBV-X gene expression. Since the HBV-X protein pos-
itivity in liver tissue in several studies, reached half of the liver
tissues specimens and X gene deregulates cell cycle control,
interferes with cellular DNA repair and apoptosis, and plays
an important role in interaction with p53 and Rb gene [49].
These ﬁndings suggested that OBI might contribute to hepato-
cyte transformation, playing a direct oncogenic role through
both its integration into the host genome and a maintained
transcriptional activity, allowing the synthesis of proteins with
potential pro-oncogenic properties.
In the current study, the predominant OBI genotypes were
HBV-genotype D and B, while HBV-genotype C and A were
less predominant and mixed genotypes were much less pre-
dominant. Similar results were found in the study of Hassan
et al. [31]. Also, Zekri et al. [50] reported that the prevalence
of mixed genotype infections was 15.7% especially those with
chronic active hepatitis. However, Vivekanandan et al. [51]
found that the predominant genotype was genotype A fol-
lowed by genotype D. Roman et al. [37] studied OBI genotypes
among native Mexican populations (Nahuas and Huichol) and
found that Nahuas had HBV/H the predominant genotype fol-
lowed by genotypes D, C, B, A while Huichol had HBV/A as
the predominant genotype followed by D, G and H. Further-
more, Candotti et al. [52] found that HBV genotypes B and C
were dominant. De Albuquerque et al. [53] and Matos et al.
[38] found that Genotype D was the most common, followed
by genotype A among OBI patients.
In this study, comparative study between characteristics of
the HBV DNA-positive and DNA-negative patients revealed
statistically highly signiﬁcant difference as regards the age, pro-
thrombin time and the platelet counts (p< 0.001). While, total
bilirubin, direct bilirubin, albumin and serumHCVRNA levelsshowed signiﬁcant difference. However, there was non signiﬁ-
cant difference regarding gender, ALT, AST and ALP.
In agreement with previous reports by Fukuda et al. [54]
and Mrani et al. [55] who showed that serum HCV-RNA load
was signiﬁcantly higher in CHC OBI-positive patients than in
negative ones. Also, Matsuoka et al. [28] reported that only the
age of the HBV DNA-positive and DNA-negative patients and
their platelet counts differed signiﬁcantly, while, ALT, AST,
ALP did not differ signiﬁcantly. Studies that were done by Sil-
va et al. [33] and Torbenson et al. [56] did not report a strong
correlation between ALT/AST levels and occult hepatitis B. In
addition, Sheneef et al. [57] reported that there was no signif-
icant difference between chronic HCV patients with or without
occult HBV infection in terms of clinical characteristics includ-
ing gender, AST, ALT and ALP.
In contrast with other studies [28,34,58–61] no statistically
signiﬁcant differences were found as regards serum HCV-
RNA load in CHC OBI-positive and negative patients. Hollin-
ger and Sood [21] reviewed several cross-sectional studies
where it was suggested that HBV replication accounts for
many of the ALT ﬂares that occur in patients with HCV. Also,
Sheneef et al. [57] reported that there was no signiﬁcant differ-
ence between chronic HCV patients with or without occult
HBV infection as regards age, serum albumin, total bilirubin
and HCV viral load.
Comparison between patients with different grades of necr-
oinﬂammatory activity and stages of ﬁbrosis regarding pres-
ence of OBI was done in this study. We noticed that there
was an increase in the percentage of positive intrahepatic
HBV-DNA samples with severe necroinﬂammatory activity
and severe ﬁbrosis.
Similar observations were made by other authors
[8,23,61,62]. Similarly, OBI accelerates the progression of cir-
rhosis, hepatic decompensation and HCC as reported by other
studies [63,64]. Cirrhosis is considered as an important risk fac-
tor for the development of HCC [60,65]. In addition, OBI may
favor neoplastic transformation in HCV-infected patients
through its contribution to cirrhosis. Many epidemiologic
and molecular studies indicate that persistent HBV infection
may have a critical role in the development of HCC in
HBsAg-negative patients [66].
Detection of occult HBV infection by nested PCR assay among chronic hepatitis C patients 359However, other studies that were done by Georgiadou et al.
[27], Kao et al. [34] and Fabris et al. [58] did not ﬁnd any asso-
ciation between OBI and severity of chronic liver disease. Also,
Chen et al. [59] reported that patients with both OBI and HCV
infection had lower liver histology activity index and ﬁbrosis
scores than those with HCV monoinfection.
In conclusionOBI is a fact in our community; it was detected
in liver tissue of HCV-infected patients, especially in cases of
HCC. In addition, OBI might be related to severity of necroin-
ﬂammatory activity and ﬁbrosis. Large studies are needed to
conﬁrm that co-infection could determine a worse progress of
chronic liver disease in this population. Also, detection of intra-
hepatic HBV-DNA is more useful in diagnosis of OBI.5. Recommendation
Intrahepatic HBV-DNA detection is recommended for diagno-
sis of occult HBV infection. However, if a liver biopsy specimen
is not available, analysis of serum samples should be performed
with a highly sensitive and speciﬁc approach based on nested
PCR or real time PCR. It is recommended to perform serum
HBV detection at different time points because the analysis of
only one sample, drawn before therapy, could not be sufﬁcient
to detect OBI if virus replication is intermittent. A closer fol-
low-up is recommended in patients with positive results of
OBI test for the potential risk of HCC development.References
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